Company intelligence / Profile preview

ReconstratA

Baltimore, Maryland, United Statesreconstrata.com ↗

Ownership: Private
Development stage: Preclinical

Overview

ReconstratA develops innovative medical devices and engineering solutions primarily for plastic and reconstructive surgery. Their lead product "AuryzoN" targets facial cartilage reconstruction procedures such as ears, noses, and eyelids. The company emphasizes user-friendly design and aims to advance healthcare through practical innovation. There are no published clinical trial results typical of pharmaceutical companies; the company positions its products as next-generation standards in surgical care.

Therapeutic areas: Other
Modalities: DeviceBiomedical engineering solution
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on ReconstratA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReconstratA.

Explore the full profile